Patrick Schöffski1, Agnieszka Wozniak2, Bernard Escudier3, Piotr Rutkowski4, Alan Anthoney5, Sebastian Bauer6, Jozef Sufliarsky7, Carla van Herpen8, Lars H Lindner9, Viktor Grünwald10, Branko Zakotnik11, Evelyne Lerut12, Maria Debiec-Rychter13, Sandrine Marréaud14, Michela Lia14, Tiana Raveloarivahy14, Sandra Collette14, Laurence Albiges3. 1. University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium; KU Leuven, Laboratory of Experimental Oncology, Department of Oncology, Leuven, Belgium. Electronic address: patrick.schoffski@uzleuven.be. 2. KU Leuven, Laboratory of Experimental Oncology, Department of Oncology, Leuven, Belgium. 3. Gustave Roussy, Department of Medical Oncology, Villejuif, France. 4. Maria Sklodowska-Curie Institute-Oncology Center, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland. 5. Leeds Teaching Hospitals National Health Service Trust, Institute of Oncology, St. James's University Hospital, Leeds, United Kingdom. 6. West German Cancer Center, University Hospital, Department of Internal Medicine, University of Duisburg-Essen, Germany and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany. 7. National Cancer Institute, Bratislava, Slovakia. 8. Radboud University Medical Center, Department of Medical Oncology, Nijmegen, The Netherlands. 9. Klinikum der Universität München, Medizinische Klinik III, Campus Grosshadern, München, Germany. 10. Hannover Medical School, Department of Haematology, Haemostasis and Oncology, and Stem Cell Transplantation, Hannover, Germany. 11. The Institute of Oncology, Department of Medical Oncology, Ljubljana, Slovenia. 12. University Hospitals Leuven, Department of Pathology, Leuven, Belgium. 13. KU Leuven, Department of Human Genetics, Leuven, Belgium. 14. European Organization for Research and Treatment of Cancer, Brussels, Belgium.
Abstract
PURPOSE: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). EXPERIMENTAL DESIGN: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed to MET+/MET- sub-cohorts by the sequencing of exons 16-19 of the MET gene in tumour tissue. The primary end-point was objective response rate (ORR). If at least two of the first 12 eligible and evaluable MET+ patients achieved a confirmed partial response (PR) or complete response (CR) (in accordance with the Response Evaluation Criteria in Solid Tumours, version 1.1), a maximum of 35 patients were enrolled. Secondary end-points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), PFS rate (PFSR), overall survival (OS) and safety. RESULTS: Forty-one patients provided consent, of whom 23 were eligible, treated and evaluable. In four MET+ patients, two achieved PR and one had stable disease (SD) (ORR 50%; 95% confidence interval [CI]: 6.8-93.2), DOR was 21.8 and 37.3 months, 1-year PFSR: 75.0% (95% CI: 12.8-96.1) and 1-year OS: 75.0% (95% CI: 12.8-96.1). Among 16 MET- patients, one achieved a PR lasting more than 9.9 months and 11 had SD (ORR: 6.3%; 95% CI: 0.2-30.2), 1-year PFSR: 27.3% (95% CI: 8.5-50.4) and 1-year OS: 71.8% (95% CI: 41.1-88.4). Among three patients with unknown MET status (MET?) due to technical failure, one achieved PR lasting more than 6.9 months, and one had SD (ORR 33.3%, 95% CI: 0.8-90.6), 1-year PFSR: 66.7% (95% CI: 5.4-94.5) and 1-year OS: 100%. MET amplification was found post hoc in one MET+ patient (PR, DOR: 37.3 months), and one MET- case who had SD. Common treatment-related adverse events were oedema (47.8%), fatigue (47.8%), nausea (39.1%), diarrhoea (39.1%) and blurred vision (34.8%). CONCLUSION: Crizotinib is active and well tolerated in advanced, metastatic PRCC1, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification. Sporadic, durable responses are also seen in MET- and MET? cases, suggesting the presence of other alterations of MET or alternative pathways.
PURPOSE:Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-). EXPERIMENTAL DESIGN: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Patients were attributed to MET+/MET- sub-cohorts by the sequencing of exons 16-19 of the MET gene in tumour tissue. The primary end-point was objective response rate (ORR). If at least two of the first 12 eligible and evaluable MET+ patients achieved a confirmed partial response (PR) or complete response (CR) (in accordance with the Response Evaluation Criteria in Solid Tumours, version 1.1), a maximum of 35 patients were enrolled. Secondary end-points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), PFS rate (PFSR), overall survival (OS) and safety. RESULTS: Forty-one patients provided consent, of whom 23 were eligible, treated and evaluable. In four MET+ patients, two achieved PR and one had stable disease (SD) (ORR 50%; 95% confidence interval [CI]: 6.8-93.2), DOR was 21.8 and 37.3 months, 1-year PFSR: 75.0% (95% CI: 12.8-96.1) and 1-year OS: 75.0% (95% CI: 12.8-96.1). Among 16 MET- patients, one achieved a PR lasting more than 9.9 months and 11 had SD (ORR: 6.3%; 95% CI: 0.2-30.2), 1-year PFSR: 27.3% (95% CI: 8.5-50.4) and 1-year OS: 71.8% (95% CI: 41.1-88.4). Among three patients with unknown MET status (MET?) due to technical failure, one achieved PR lasting more than 6.9 months, and one had SD (ORR 33.3%, 95% CI: 0.8-90.6), 1-year PFSR: 66.7% (95% CI: 5.4-94.5) and 1-year OS: 100%. MET amplification was found post hoc in one MET+ patient (PR, DOR: 37.3 months), and one MET- case who had SD. Common treatment-related adverse events were oedema (47.8%), fatigue (47.8%), nausea (39.1%), diarrhoea (39.1%) and blurred vision (34.8%). CONCLUSION:Crizotinib is active and well tolerated in advanced, metastatic PRCC1, achieving objective responses and long-lasting disease control in patients with MET mutations or amplification. Sporadic, durable responses are also seen in MET- and MET? cases, suggesting the presence of other alterations of MET or alternative pathways.
Authors: Nieves Martínez Chanzá; Wanling Xie; Mehmet Asim Bilen; Hannah Dzimitrowicz; Jarred Burkart; Daniel M Geynisman; Archana Balakrishnan; I Alex Bowman; Rohit Jain; Walter Stadler; Yousef Zakharia; Vivek Narayan; Benoit Beuselinck; Rana R McKay; Abhishek Tripathi; Russell Pachynski; Andrew W Hahn; JoAnn Hsu; Sumit A Shah; Elaine T Lam; Tracy L Rose; Anthony E Mega; Nicholas Vogelzang; Michael R Harrison; Amir Mortazavi; Elizabeth R Plimack; Ulka Vaishampayan; Hans Hammers; Saby George; Naomi Haas; Neeraj Agarwal; Sumanta K Pal; Sandy Srinivas; Benedito A Carneiro; Daniel Y C Heng; Dominick Bosse; Toni K Choueiri; Lauren C Harshman Journal: Lancet Oncol Date: 2019-02-28 Impact factor: 41.316
Authors: Siddhartha Devarakonda; Sumithra Sankararaman; Brett H Herzog; Kathryn A Gold; Saiama N Waqar; Jeffrey P Ward; Victoria M Raymond; Richard B Lanman; Aadel A Chaudhuri; Taofeek K Owonikoko; Bob T Li; John T Poirier; Charles M Rudin; Ramaswamy Govindan; Daniel Morgensztern Journal: Clin Cancer Res Date: 2019-07-12 Impact factor: 12.531
Authors: Sumanta K Pal; Catherine Tangen; Ian M Thompson; Naomi Balzer-Haas; Daniel J George; Daniel Y C Heng; Brian Shuch; Mark Stein; Maria Tretiakova; Peter Humphrey; Adebowale Adeniran; Vivek Narayan; Georg A Bjarnason; Ulka Vaishampayan; Ajjai Alva; Tian Zhang; Scott Cole; Melissa Plets; John Wright; Primo N Lara Journal: Lancet Date: 2021-02-13 Impact factor: 79.321
Authors: Darren R Feldman; Yasser Ged; Chung-Han Lee; Andrea Knezevic; Ana M Molina; Ying-Bei Chen; Joshua Chaim; Devyn T Coskey; Samuel Murray; Satish K Tickoo; Victor E Reuter; Sujata Patil; Han Xiao; Jahan Aghalar; Arlyn J Apollo; Maria I Carlo; Robert J Motzer; Martin H Voss Journal: Cancer Date: 2020-09-25 Impact factor: 6.860
Authors: Toni K Choueiri; Daniel Y C Heng; Jae Lyun Lee; Mathilde Cancel; Remy B Verheijen; Anders Mellemgaard; Lone H Ottesen; Melanie M Frigault; Anne L'Hernault; Zsolt Szijgyarto; Sabina Signoretti; Laurence Albiges Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777